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Available online xxxxBackground:Westudied the effect of bioresorbable vascular scaffold (BVS) implantation on distal coronary endo-
thelial function, in swine on a high fat diet without (HFD) or with diabetes (DM + HFD).
Methods: Five DM+HFD and ﬁveHFD swine underwent BVS implantation on top of coronary plaques, andwere
studied six months later. Conduit artery segments N5 mm proximal and distal to the scaffold and corresponding
control segments of non-scaffolded coronary arteries, as well as segments of small arteries within the ﬂow-
territories of scaffolded and non-scaffolded arteries were harvested for in vitro vasoreactivity studies.
Results: Conduit segments proximal and distal to the BVS edges showed reduced endothelium-dependent
vasodilation as compared to control vessels (p b 0.01), with distal segments being most prominently affected
(p b 0.01). Endothelial dysfunction was only observed in DM+ HFD swine and was principally due to a loss of
NO. Endothelium-independent vasodilation and vasoconstriction were unaffected. Surprisingly, segments from
themicrocirculation distal to the BVS showed enhanced endothelium-dependent vasodilation (p b 0.01), where-
as endothelium-independent vasodilation and vasoconstriction were unaltered. This enhanced vasorelaxation
was only observed in DM+ HFD swine, and did not appear to be either NO- or EDHF-mediated.
Conclusions: Sixmonths of BVS implantation inDM+HFD swine causes NO-mediated endothelial dysfunction in
nearby coronary segments, which is accompanied by a, possibly compensatory, increase in endothelial function
of the distal microcirculation. Endothelial dysfunction extending into coronary conduit segments beyond the
implantation-site, is in agreement with recent reports expressing concern for late scaffold thrombosis and of
early BVS failure in diabetic patients.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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DiabetesDrug-eluting stents (DES) are widely used for the treatment of ob-
structive coronary artery disease (CAD), including in patients with dia-
betes mellitus (DM) [1]. However, the use of, in particular ﬁrst
generation, DES has raised concern regarding long-term endothelialott Vascular (Grant No: CP001 /
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nt J Cardiol (2017), https://dodysfunction adjacent to the stent including the distal microcirculation
[2,3], which could be related to adverse events including late stent
thrombosis [4]. Second generation DES have partially succeeded in re-
ducing thrombosis, however paradoxical vasoconstriction adjacent to
the stent has still been reported [4–6].
The everolimus-eluting bioresorbable vascular scaffold (BVS) has
been introduced with the aim to provide temporary vessel scaffolding
and to be subsequently resorbed over time with restoration of
vasomotion. Indeed, the ABSORB trials have demonstrated efﬁcacy for
the treatment of simple CAD in selected DM and non-DM patients up
to ﬁve years with some restoration of vasomotion [7–10]. Conversely,
paradoxical vasoconstriction has also been observed within the scaffold
and adjacent segments even at ﬁve years after implantation [7,8],e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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higher rates of BVS thrombosis have recently been reported in unselected
populations and in meta-analyses of all randomized trials up to
24 months after BVS implantation as compared to a speciﬁc second gen-
eration DES [11–13], as well as lack of superior vasomotor reactivity after
36 months [14] and still incomplete vasomotion after 5 years [9]. There-
fore, endothelial dysfunction with its subsequent associated adverse
events still remains an issue, also after BVS implantation. Moreover,
whether BVS affects endothelial function in the distal perfusion territory
of the scaffold is presently unknown. This is of importance since a healthy
microcirculation plays a key role in the regulation of optimal myocardial
perfusion [15], also after percutaneous coronary intervention (PCI).
A signiﬁcant proportion of PCIs involves DMpatients that experience
a higher incidence of treatment failure, including stent thrombosis [1].
Indeed, DM has been shown to be an independent predictor of
revascularisation failure six months after BVS implantation [11]. DM
and endothelial dysfunction are closely related [16]. However, in the
setting of DM, detailed studies of endothelial function of both coronary
macro- and micro-circulation in the restoration phase of the BVS are
currently lacking.
Swine are an excellent model for the evaluation of coronary scaffolds
because of the anatomical similarities between porcine and human cor-
onary arteries [17,18]. In addition, DM-induction in combination with a
high fat diet (HFD) is known to generate atherosclerosis, and speciﬁc
components of endothelial function can be studied to unravel underlying
mechanisms [19,20]. Although the effects of BVS implantation have been
studied in healthy swine, showing resemblance to the human situation
including lack of vasomotion of the scaffold six months after implanta-
tion [17,18], details regarding endothelial function in the restoration
phase in an atherosclerosis model with and without DM are currently
lacking. Consequently, the present study was undertaken to evaluate
in vitro the effect of BVS on adjacent endothelial function, as well as of
thedistalmicrocirculation, sixmonths after implantation in dyslipidemic
swine with or without DM.
1. Methods
1.1. Study device
The ABSORB™ BVS (Abbott Vascular, USA) is a balloon-expandable, fully bioresorba-
ble scaffold that consists of a poly (L-lactide) backbonewith a poly (D,L-lactide) coating in a
1:1 ratio with everolimus.
1.2. Experimental design
The protocol was approved by the local animal ethics committee and the study was
performed according to the National Institutes of Health guide for the care and use of Lab-
oratory animals. The protocol has been described in detail elsewhere [19–21]. In short, ten
male crossbred (Yorkshire × Landrace) swine were fed a cholesterol-rich diet (HFD). Five
animalswere renderedDM(DM+HFD) by a single-dose injection of streptozotocin. After
nine months of atherogenesis, quantitative coronary angiography (QCA) was performed.
All anesthetized swine (isoﬂurane, 1–2.5% v/v) received randomly assigned single 3.0
× 18.0 mm BVS implants in two epicardial coronary arteries with a scaffold to artery
ratio of 1.1 on top of an atherosclerotic lesion, based on the angiogram, with follow up
(FU) of six months. The untreated coronary artery served as a control. After stent implan-
tation, all swine received acetylsalicylic acid (300mg) and clopidogrel (75mg) once daily.
Blood samples were obtained, as published previously [19,20]. Also, plasma von
Willebrand factor (vWf) levels were determined as described previously [22].
At six months FU, QCA was repeated in anesthetized swine (pentobarbital sodium
20 mg ∙kg−1 ∙h−1) and afterwards they were euthanized. The hearts were excised and
placed in Krebs buffer [3,19]. Of each animal, one coronary artery treated with a BVS and
oneuntreated arterywere used. Segments of epicardial conduit arteries (N2mmdiameter)
of a BVS treated artery, located N5 mm proximal or distal to the scaffold's edges, were iso-
lated. Also, segments of the untreated artery at approximately similar locations were ob-
tained. In addition, segments of epicardial small arteries (~300 μm diameter) in the
distal ﬂow area of the scaffold and of a similar location of the untreated control artery
were dissected out for subsequent functional studies. The scaffold, including immediately
adjacent ~5 mm proximal and distal vessel segments, was used in a separate study [21].
1.3. Quantitative coronary angiography
QCA analysis was performed by the Coronary Angiographic Analysis System (CAAS,
version 5.9.2 Pie Medical Imaging BV, The Netherlands). After maximal vasodilationPlease cite this article as: M. van den Heuvel, et al., The effect of bioreso
function in dyslipidemic swine with and ..., Int J Cardiol (2017), https://dowith isosorbide dinitrate (1 mg/artery i.c.), minimal and maximal lumen diameter were
measured both proximal and distal to the BVS and in corresponding segments of
unscaffolded reference coronary arteries.
1.4. In vitro coronary conduit and small arterial function assessment
Segments of conduit arteries (~4 mm length) were suspended in organ baths. Seg-
ments of small arteries (~2 mm length) were mounted in Mulvany wire-myographs
(DMT, Denmark). Vascular responses were measured as changes in isometric force. Both
conduit and small arteries were subjected to the same experimental protocol as described
previously [3,19]. In short, after determination of the maximal contractile response to
0.1 mol/l potassium chloride (KCl), concentration-response curves (CRCs) were acquired
using separate, in vivo adjacently positioned, segments. Endothelium-dependent relaxa-
tion to bradykinin (BK, 10−10–10−6 mol/l) was recorded upon pre-constriction by the
thromboxane analogue U46619 (10−6 mol/l) in a ﬁrst set of segments. In order to deter-
mine nitric oxide (NO) dependent and NO-independent contributions, in a second set,
theCRC for BKwas constructed after 30minof pre-incubationwith theNO-synthase inhib-
itor N-nitro-L-arginine methyl ester (L-NAME, 10−4 mol/l) to block endogenous NO-
production. From a third set, endothelium-independent but NO-mediated vasodilation to
S-nitroso-N-acetylpenicillamine (SNAP, 10−9–10−5 mol/l) was measured. Finally, CRCs
for endothelin-1 (ET-1, 10−10–10−7 mol/l) were constructed to study vasoconstriction in
a fourth set of vessel segments.
In addition, small arteries were subjected to an extended protocol, due to availability of
more vessel-segments and experimental set-ups, to study endothelial function inmore de-
tail. Additional sets of segmentswere incubatedwith the small conductance Ca2+-activated
K+-channel inhibitor apamin (APA,10−7 mol/l), together with the intermediate conduc-
tance Ca2+-activated K+-channel inhibitor TRAM34 (10−5 mol/l) to block the
endothelium-derived hyperpolarizing factor (EDHF) component of BK-induced relaxation
[23] alone or in combination with L-NAME. This combination of blockers has previously
been shown to almost completely abolish BK-induced vasodilation [19]. All reagents used
were obtained from Sigma-Aldrich, The Netherlands.
1.5. Histology
Finally, conduit arterial segments were formaldehyde-ﬁxed and stained en face with
Oil-red-O (Sigma, The Netherlands) as a macroscopic stain of fat accumulation or stained
with resorcin-fuchsin as a microscopic overview stain. Morphometry of the Oil-red-O
staining was performed by measuring total area and stained area with an image analysis
system (Clemex Technologies Inc., Canada) and data are presented as percentage lipid
area.
1.6. Data analysis
Values are presented as mean ± SEM. Differences between outcome variables were
analysed using paired t-testing, after normal distribution of data was conﬁrmed with
Komolgorov-Smirnov normality test. Vasodilator responses to BK and SNAPwere expressed
as percentage of pre-constriction to U46619. Vasoconstriction to ET-1was normalized to the
response to 0.1mol/l KCl. Statistical analysis of CRCswas performed using two-way ANOVA,
followed by Bonferroni's post hoc correction (StatView). P b 0.05 (two-tailed) was consid-
ered statistically signiﬁcant.
2. Results
2.1. Model characteristics
Both DM+HFD and HFD swine showed elevated cholesterol levels,
and only DM+HFD swine showed high glucose levels [19–21]. Plasma
vWf-levels increased over time in bothDM+HFD (0.28±0.02 IU/ml at
implantation; 0.34 ± 0.01 IU/ml at 6 months FU, p b 0.05) and
HFD swine (0.30 ± 0.04 IU/ml at implantation, 0.37 ± 0.02 IU/ml
at 6 months FU, p b 0.05), without a difference between the groups
(p N 0.1).
2.2. QCA analysis
At 6 months FU, calculated mean lumen diameters both proximal
and distal to the BVS were similar between BVS-treated coronaries
and corresponding segments in non-scaffolded coronaries in DM
+HFD and HFD animals (example shown in Fig. 1A). Mean lumen di-
ameters of vessels used in the functional experiments were similar
between groups (DM+HFD proximal to BVS: 4.06± 0.25 vs. Control
proximal: 3.38 ± 0.46 mm; DM + HFD distal to BVS: 2.66 ± 0.26 vs.
Control distal: 2.37± 0.34mm; HFD proximal to BVS: 3.53± 0.42 vs.
Control proximal 3.50 ± 0.04 mm; HFD distal to BVS: 2.09 ± 0.18 vs.
Control distal 2.74 ± 0.41 mm; all, p N 0.1).rbable vascular scaffold implantation on distal coronary endothelial
i.org/10.1016/j.ijcard.2017.11.037
Fig. 1.Representative angiogramwith depicted vessel segments located N5mmproximal (delineated by the dashedwhite lines A–A) and distal (delineated by the dashed red lines C–C) to
the BVS edges (delineated by the dashed yellow lines B–B), or corresponding segments of the reference (control) artery fromwhich themean lumen diameters were calculated (panel A).
Representative segments (opened longitudinally), showing macroscopic fatty streaks, as visualized by en face Oil-red-O staining (panel B), and representative cross-sections (resorcin-
fuchsin staining) showing plaques with different degrees of complexity from DM + HFD (panels C–J) and HFD (panels K–S) swine. ⁎Indicates plaque. Arrows indicate endothelial
lining. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 2. Detailed coronary conduit artery function located N5 mm distal to the BVS and in control arteries, in dyslipidemic swine with or without DM. Figure highlighting the effects of six
months of BVS implantation on BK-mediated vasodilation (A, D), SNAP-mediated vasodilation (B, E), and ET-1 mediated vasoconstriction (C, F) of distal conduit segments of DM+HFD
(A-C) and HFD swine (D-F). Figure also highlighting the effect of DM+HFD on conduit arterial function of control segments (A–C) vs. HFD control segments (D–F). ⁎p b 0.01 DM+HFD
BVS vs. DM+HFDControl; †p=0.051DM+HFDControl vs. HFDControl. BK=bradykinin, BVS=bioresorbable vascular scaffold, DM=diabetesmellitus, ET-1= endothelin-1, HFD=
high fat diet, n = number of animals, SNAP = S-nitroso-N-acetylpenicillamine.
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Contractile responses to KCl and U46619 were not signiﬁcantly dif-
ferent between vessel segments of BVS-treated and control coronaries
of DM + HFD and HFD swine, both for conduit and small arteries
(data not shown).2.3.1. Conduit arteries
DM on top of HFD slightly enhanced BK-induced dilation in con-
trol arteries (Fig. 2). BVS markedly blunted BK-induced vasodilation
in DM+ HFD swine, without altering the BK-response in HFD swine
(Fig. 2). In accordance with previous studies from our laboratory [3],
the BVS-induced attenuation of BK-mediated vasodilation was more
pronounced in distal conduit artery segments as compared to prox-
imal segments (Suppl. Fig. 1). Consequently, Fig. 2 only shows the
responses in conduit artery segments located distal to the BVS, and
vascular function was studied in more detail in these segments.
Responses to SNAP and ET-1 were unaffected by either DM or BVS
as compared to control vessels, indicating a BK-speciﬁc effect
(Fig. 2).
L-NAME reduced BK-induced vasodilation under all conditions
(Fig. 3). However, BVS signiﬁcantly attenuated the surface area
encompassed by the BK-response curves in the presence and absence
of L-NAME in DM + HFD swine, so that the smallest NO-dependent
area under the curve was observed in BVS treated vessels (25 ± 9), as
compared to control vessels (101 ± 18) in DM + HFD swine andPlease cite this article as: M. van den Heuvel, et al., The effect of bioreso
function in dyslipidemic swine with and ..., Int J Cardiol (2017), https://docompared to BVS-treated vessels in HFD swine (56 ± 8; both p b
0.05). These observations indicate that loss of NO contributed to the
blunted BK-induced vasodilation in conduit artery segments located
N5 mm distal to the BVS in DM+ HFD swine (Fig. 3).
2.3.2. Small arteries
In HFD swine, BVS did not alter the response to BK in small arter-
ies of the microcirculation distal to the BVS (Fig. 4). However, in HFD
+ DM swine, BVS signiﬁcantly enhanced the response to BK, both
versus its own control and versus the BVS group of HFD swine
(Fig. 4A, E). This difference remained apparent during L-NAME,
TRAM34 and apamin, and the combination of these inhibitors. Inhi-
bition of eNOS, with or without concomitant EDHF blockade, re-
duced the responses to BK, the largest reductions being observed in
the presence of all inhibitors. However, this reduction appeared
smaller in the BVS group of DM+HFD swine, indicating a remaining
non-NO/non-EDHF mediated component of the BK-response, al-
though this failed to reach statistical signiﬁcance (Fig. 4A–H). Re-
sponses to SNAP (Fig. 4I, J) and ET-1 (Fig. 4K, L) were unaltered by
either DM or BVS.
2.4. Histology
The Oil-red-O area was similar in conduit arterial segments
located N5 mm distal to the BVS implant as compared to control coro-
nary conduit arteries in both DM + HFD and HFD swine respectivelyrbable vascular scaffold implantation on distal coronary endothelial
i.org/10.1016/j.ijcard.2017.11.037
Fig. 3.NO- and non NO-mediated endothelial function located N5mmdistal to the BVS and in control arteries, in dyslipidemic swinewith orwithout DM. Figure highlighting the effects of
sixmonths of BVS implantation onNO-mediated endothelium-dependent vasodilation of distal conduit segments of DM+HFD (A, B) and HFD swine (C, D). The grey area in between the
BK and L-NAME curves depicts the speciﬁc contribution of the NO-mediated component of the BK-response. ⁎p b 0.05 area DM+HFD BVS vs. area DM+HFD Control; †p b 0.05 area DM
+ HFD BVS vs. area HFD BVS; ‡p b 0.05 BK vs. BK + L-NAME. Abbreviations as in Fig. 2. In addition: L-NAME = N-nitro-L-arginine methyl ester, NO = nitric oxide.
5M. van den Heuvel et al. / International Journal of Cardiology xxx (2017) xxx–xxx(DM+HFD: BVS vs. Control: 30±7% vs. 27±8%, HFD: BVS vs. Control:
30± 6% vs. 26± 9%; all p N 0.1). Representative segments are shown in
Fig. 1B.
As published previously [20], plaques with different degrees of
complexity were observed to a similar extent in the coronary conduit
arteries from DM + HFD and HFD swine, with presence of intact
endothelium in both the lesion area as well as in the structurally un-
altered vessel wall. Representative examples are shown in Fig. 1C–J,
K–S. Also, as reported previously [19], coronary small arteries of both
groups showed fatty streak lesions. The effect of BVS implantation on
the atherosclerosis process distal to the BVS was not studied in detail
in the present study.
3. Discussion
In the present study, we evaluated the effects of BVS implantation
on endothelial function in vitro, of the vasculature located in the
proximity (N5 mm from the edges) of the implanted BVS in a dyslipid-
emic swine model with or without DM. We hypothesized that the
coronary circulation distal to the BVS would be at increased risk
for endothelial dysfunction, especially in DM. The main ﬁndings
were that: (i) only in the presence of DM, coronary conduit arteriesPlease cite this article as: M. van den Heuvel, et al., The effect of bioreso
function in dyslipidemic swine with and ..., Int J Cardiol (2017), https://doshowed decreased endothelium-dependent vasodilation, particularly
distal to the BVS. This was principally due to loss of NO-mediated
dilation; (ii) interestingly, the microcirculation within the distal perfu-
sion territory showed slightly enhanced endothelium-dependent vaso-
dilation that appeared to be independent of NO- or EDHF-mediated
mechanisms.
In the present animal model, the high fat diet resulted in a similar
degree of non-obstructive coronary atherosclerosis in DM+ HFD com-
pared to HFD swine [19,20], aswell as increased plasma vWf-levels over
time, indicating systemic endothelial dysfunction associated with CAD
development [24]. In contrast, speciﬁc components of both systemic
and coronary microvascular function were altered only in the presence
of DM, similar to diabetic patients [19,25], making it a relevant model
for the study of coronary interventions in the context of CAD and DM.
BVS implantation within this model resulted in a similar vascular
healing response with or without DM, with a heterogeneous coverage
of the scaffold and a low polymer mass loss of the BVS at six months
[21]. Therefore, the scaffold is likely to be immobile at this time-point
according to prior results [8,18], although we did not perform
vasomotion experiments to conﬁrm this. For the present study, we fo-
cused on coronary vascular function in the segments located N5 mm
from the scaffold's edges.rbable vascular scaffold implantation on distal coronary endothelial
i.org/10.1016/j.ijcard.2017.11.037
Fig. 4.Detailed coronary small arterial function in the distal perfusion area of the BVS and in control segments, in dyslipidemic swinewith orwithout DM. Figure highlighting the effects of
BVS on endothelium-dependent BK-induced vasodilation (A, E) after speciﬁc blockers (B, C, D, F, G, H), as well as endothelium-independent SNAP-induced vasodilation (I, J) and ET-1-
induced vasoconstriction (K, L) of segments from the distal coronary microcirculation of DM+ HFD (A, B, C, D, I, K) and HFD swine (E, F, G, H, J, L). Figure also highlighting the effect
of DM+ HFD on BK-mediated small arterial function distal to BVS (A) vs. BVS-treated vessels of HFD swine (E). L-NAME: blockage of endogenous NO (B, F). TRAM+ APA: blockage of
speciﬁc EDHFs (C, G). L-NAME + TRAM+ APA: blockage of both endogenous NO and of speciﬁc EDHFs (D, H). ⁎p b 0.01 DM+ HFD BVS vs. DM + HFD Control; †p b 0.05 DM+ HFD
BVS vs. DM + HFD Control; ‡p b 0.01 DM + HFD BVS vs. HFD BVS. Abbreviations as in Fig. 2. In addition: EDHF = endothelium-derived hyperpolarizing factor, TRAM + APA =
TRAM34 and apamin.
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endothelium-dependent vasodilation distal to the BVS. This impairment
is in accordance with previous DES-studies, which also showed
endothelial dysfunction in the peri-stent area, particularly in the distal
segment, 6–16months after implantation, in particular for ﬁrst genera-
tion [2], and less extensively also for second generation [4–6] DES. In ad-
dition, endothelial dysfunction has also been demonstrated adjacent to
the BVS, with signs of improvement up to ﬁve years after implantation
[7–9,14]. Overall, these clinical studies demonstrated impaired adjacent
vasomotion in small groups of both DM and non-DM patients, which
were too limited to examine the subgroup of DM speciﬁcally. However,
a relation between DM and early BVS failure has been observed [11]. In
addition, none of these studies addressed vascular responsiveness of the
untreated vessel as a control. This is relevant since atherosclerosis can
also result in endothelial dysfunction,whichmakes it difﬁcult to directly
relate the observed vascular effects to the intervention per se. In the
present study, six months of BVS implantation without DM did not af-
fect adjacent endothelial function, which is in accordance with the
results found by Gogas et al., one and two years after scaffold implanta-
tion in a healthy porcine model [17]. These observations suggest that
our ﬁndings are speciﬁc to BVS combined with DM. Indeed, DM is
known to complicate PCI success as shown by a reduced clinicalPlease cite this article as: M. van den Heuvel, et al., The effect of bioreso
function in dyslipidemic swine with and ..., Int J Cardiol (2017), https://dooutcome after two years in a large DES-study [26], as well as being an
independent predictor of treatment failure up to one year after BVS im-
plantation [11], highlighting again the interaction of DES, including BVS,
with DM.
Speciﬁcally, in the present study, we showed that the endothelial im-
pairment was caused by a reduced NO-mediated vasodilation. Impair-
ment of NO bioavailability adjacent to DES has been described before
[27]. Increased inﬂammation and oxidative stress due to vascular injury
caused by the procedure, drug or other components of the BVS, have
been proposed as possible mechanisms [27–29]. While everolimus has
been shown to reduce NO-release [30], it is unlikely that the drug is re-
sponsible for this effect six months after implantation, as most of it has
been released from the scaffold after threemonths [31]. Other scaffold re-
lated processes, including a change in regional wall shear stress and the
consequent alterations in local gene expression [32], could also have con-
tributed to the loss of NO synthase activity, although this does not readily
explain why this was observed only in the DM+ HFD-group. Recently,
the AIDA trial was halted after two years due to safety concerns of the
BVS with a higher incidence of scaffold thrombosis as compared to the
metallic everolimus-coated DES [12]. A recent meta-analysis of all
randomized BVS trials to date reported a similar concern for BVS as com-
pared to its DES counterpart in clinical practice [13]. This further indicatesrbable vascular scaffold implantation on distal coronary endothelial
i.org/10.1016/j.ijcard.2017.11.037
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products or the resulting pathology may be responsible for the observed
endothelial dysfunction. These effects are thought to extend downstream
through accumulation and diffusionwithin the vasa vasorum, explaining
the more pronounced distal effects. Furthermore, DM is known to be
strongly associated with NO-mediated endothelial dysfunction [16],
although we did not ﬁnd any evidence of DM-induced altered NO-
mediated coronary function within the present model [19,20]. However,
combined effects of both BVS and DM might explain the observed re-
duced NO-availability.
To study the extent of the endothelial dysfunction, we examined
small arterial function in the distal perfusion area of the BVS. Previously,
we and others have reported distal microvascular dysfunction after ﬁrst
generation DES implantation [3,27]. Therefore, the distal microcircula-
tion is considered at increased risk of dysfunction. Surprisingly, we
found an enhanced microvascular endothelium-dependent response,
however only in the presence of reduced NO-mediated conduit endo-
thelial function. This effect can be explained by the assumption that
the distal microcirculation is reacting to the endothelial dysfunction oc-
curring more proximally. Indeed, the coronary microcirculation is
known to enable substantial variations in coronary ﬂow due to several
endothelium-dependent regulatory mechanisms including NO, EDHF,
and prostacyclins [15]. This heterogeneity supports the concept of
compensatorymechanisms that allow substitution of one dilator for an-
other in the presence of disease [33], as shown in the coronary circula-
tion of DM-patients [34]. Therefore, also within the present study, we
propose amechanismof local autoregulation of endothelial function be-
tween coronary conduit and small arteries in which a loss of NO-
mediated component in the conduit artery is compensated for by NO-,
EDHF-, and non-NO/non-EDHF-mediated components in the distal
microcirculation.
3.1. Study limitations
Although the present large animal model with cardiovascular risk
factors and early atherosclerosis does not completely mimic human ob-
structive CAD, it allows extensive functional analysis of early alterations
in coronary vascular function. However, vascular function was only
assessed in vitro. Although it is clear that in vitro several modulators
of vascular tone are altered compared to the in vivo situation, including
autonomic inﬂuences, myocardial metabolism, and blood ﬂow, the
in vitro approach allowed us to examine vascular function in parallel
and in great detail. In an in vivo setting, such extensive vascular function
studieswould be hampered both by the potential systemic effects of the
various compounds as well as by the long half-life of some of the sub-
stances and thus by the interaction of different substances within each
animal. Nevertheless, the results from the present studywarrant further
studies to examine the alterations in endothelial function produced by
the BVS inDM in vivo over an extended period of time, in order to assess
the longitudinal pattern of coronary vascular impairment following BVS
implantation.
A second limitation is that the functional measurements in isolated
coronary vessels did not allowpressure ﬁxation of the coronary vascular
bed in situ, precluding detailed quantitative investigation of BVS-
induced alterations in coronary microvascular structure.
3.2. Conclusions
This is the ﬁrst study evaluating the effect of six months of BVS-
implantation on coronary endothelial function in segments proximal
and distal to the BVS. Speciﬁcally, in the presence of DM, coronary conduit
artery segments located N5mmdistal to the BVS, showed decreased NO-
mediated vasodilation. In contrast, the coronary microcirculation in the
distalﬂowarea of the BVS showedenhanced endothelium-dependent va-
sodilation, possibly acting as a compensatory mechanism.Please cite this article as: M. van den Heuvel, et al., The effect of bioreso
function in dyslipidemic swine with and ..., Int J Cardiol (2017), https://do3.3. Perspectives
The present study demonstrates that signiﬁcant endothelial dys-
function is present in epicardial coronary artery segments located
N5 mm proximal or distal to the BVS in diabetic swine on a high fat
diet, as late as 6 months after BVS implantation. These observations
may explain, at least in part, recent clinical studies reporting late scaf-
fold thrombosis after BVS implantation aswell as early treatment failure
up to one year after BVS implantation, particularly in diabetic patients.Conﬂict of interest
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